Skip to main content
SpringerLink
Log in

On Cost Effectiveness and Sample Size in Clinical Trials. The Author’s Reply

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hart AAM, Dijkgraaf MGW. On cost effectiveness and sample size in clinical trials. Pharmacoeconomics 2004; 22 (10) 685–89

    Article  PubMed  Google Scholar 

  2. Backhouse ME. Use of randomised controlled trials for producing cost effectiveness evidence: potential impact of design choices on sample size and study duration. Pharmacoeconomics 2002; 20 (15): 1061–77

    Article  PubMed  Google Scholar 

  3. Claxton K. The irrelevance of inference: a decision making approach to the stochastic evaluation of health care technologies. J Health Econ 1999; 18: 341–64

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The views expressed in this reply are entirely those of the author and do not necessarily represent the views or practices of Novartis Pharma AG.

Author information

Authors and Affiliations

  1. Novartis Pharma AG, Pharma Affairs, Basel, Switzerland

    Martin E. Backhouse

Authors
  1. Martin E. Backhouse
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Backhouse, M.E. On Cost Effectiveness and Sample Size in Clinical Trials. The Author’s Reply. PharmacoEconomics 22, 688–689 (2004). https://doi.org/10.2165/00019053-200422100-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200422100-00007

Keywords

Search

Navigation